An inhibitory neuron called chandelier cell in the cerebral cortex of a mouse. Chandelier cells send dendrites (input apparatus) toward the surface of, and axons (output apparatus) toward the inside of, the cerebral cortex. Liu et al. report that the extra copy of the DSCAM gene in mouse models of Down syndrome increases the number of the axon terminals of chandelier cells.
Newswise — An extra copy of a gene that controls synapse formation in the cortex causes excessive inhibitory signaling and may contribute to Down syndrome, according to a new study publishing April 20th in the open access journal PLOS Biology by Bing Ye of the University of Michigan, US, and colleagues. The finding may help explain some of the neurologic consequences of the syndrome.
Down syndrome is caused by a trisomy of chromosome 21, where individuals have three rather than two copies of this chromosome. The higher dosage of every gene on chromosome 21 has multiple effects, including neurological ones, but it is unclear exactly which of the 200-300 genes are responsible for which symptoms of the condition.
Previous work, including by the authors of the new study, has shown that a gene encoding Down syndrome cell adhesion molecule (DSCAM) is likely involved in at least some neurological effects, as increased levels in animal models affect the size of presynaptic terminals (regions of neurons that release neurotransmitters to downstream neuronal receptors).
Within the brain, GABAergic synapses release GABA, an inhibitory neurotransmitter that diminishes the firing of its downstream targets. Ye and colleagues asked what the effect of DSCAM triplication was on GABAergic neurons in the neocortex, the outer layer of the brain. They crossed a female mouse carrying a mouse equivalent of chromosome 21 trisomy (used as a model of Down syndrome) with a disomic (euploid) male mouse carrying one normal DSCAM gene and one non-functional mutant gene. Thus, the offspring included euploid mice with two functional copies of DSCAM (effectively normal mice), trisomic mice with three copies of functional DSCAM (modeling Down syndrome), and trisomic mice with two functional copies of DSCAM (i.e., effectively normal for DSCAM, but not for the rest of chromosome 21).
They found that mice with three copies of a functional DSCAM gene had an increase in the number of GABAergic terminals that formed synapses on target neurons in the neocortex. Mice with two functional DSCAM genes had normal numbers of terminals, despite having elevated levels of amyloid precursor protein (APP) in the brain, another biochemical consequence of trisomy 21 (due to triplication of the APP gene).
The effect of gene triplication was seen functionally as well—mice with three copies of the gene had more inhibitory signaling in the target areas of the neocortex, suggesting that excessive DSCAM was the cause of this increased GABAergic synaptic transmission as well as the higher number of GABAergic nerve terminals. The authors found they could trigger the opposite effect (i.e. reduction of nerve terminals and loss of GABAergic signaling) if they prevented the production of normal levels of DSCAM.
“Altered DSCAM expression has been linked to multiple brain disorders,” Ye said, including Down syndrome, autism spectrum disorder, intractable epilepsy, and bipolar disorder. “Our results suggest that dysregulation of DSCAM levels may be a common pathogenic driver of GABAergic dysfunction across these conditions.”
Ye adds, “This study shows excessive inhibitory connections in the cerebral cortex of mouse models of Down syndrome, and demonstrates that the extra copy of the DSCAM gene is the cause.”
#####
Press-only preview: https://plos.io/3me4dUX
Citation: Liu H, Caballero-Florán RN, Hergenreder T, Yang T, Hull JM, Pan G, et al. (2023) DSCAM gene triplication causes excessive GABAergic synapses in the neocortex in Down syndrome mouse models. PLoS Biol 21(4): e3002078. https://doi.org/10.1371/journa
Author Countries: United States
Funding: see manuscript
Competing interests: The authors have declared that no competing interests exist.
About PLOS Biology
PLOS Biology is an open-access, peer-reviewed journal published by PLOS, featuring research articles of exceptional significance, originality, and relevance in all areas of biology. For more information visit http://journals.plos.org/plosb
Media and Copyright Information
For information about PLOS Biology relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit http://journals.plos.org/plosb
PLOS Journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited.
About PLOS
PLOS is a nonprofit, Open Access publisher empowering researchers to accelerate progress in science and medicine by leading a transformation in research communication. We’ve been breaking boundaries since our founding in 2001. PLOS journals propelled the movement for OA alternatives to subscription journals. We established the first multi-disciplinary publication inclusive of all excellent research regardless of novelty or impact, and demonstrated the importance of open data availability. As Open Science advances, we continue to experiment to provide more opportunities, choice, and context for readers and researchers. For more information, visit https://www.plos.org/who-we-ar
Disclaimer
This press release refers to upcoming articles in PLOS Biology. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
RSS